- Compared with standard pain management alone, intranasal fentanyl along with standard pain management is linked to significantly lower pain during screening of premature infants for retinopathy of prematurity (ROP).
- Risk for respiratory depression was not increased.
Why this matters
- This is the first randomized control trial (RCT) to examine the efficacy of intranasal fentanyl to reduce pain during screening for ROP.
- Study of 111 preterm infants between 30 and 34 weeks' postmenstrual age who received either intranasal fentanyl (2 μg/kg) or intranasal normal saline.
- Outcome: PIPP-R (premature infant pain profile-revised) score during the screening.
- Funding: None disclosed.
- 32% infants were born at
- Intranasal fentanyl vs standard pain management alone had:
- Lower pain during the retinal examination (PIPP-R, score 8.3 vs 11.5; P<.001>
- No significant difference for adverse effects (5.3% vs 1.8%; P=.62).
- Results may not be generalizable.
- Single-center study.
Coauthored with Vijay Rathod, PhD.